Study yields promising results for PET imaging agent flutemetamol

09/8/2010 | MarketWatch

PET imaging agent flutemetamol showed 93.1% sensitivity and 93.3% specificity in identifying patients with clinically probable Alzheimer's disease, according to a Phase II study. Scans that ran a week later on the same patient group showed similar results. "These data show that flutemetamol exhibits equivalent brain uptake to that of its parent molecule, 11C-Pittsburgh compound B, while also providing high test-retest replicability and potentially greater accessibility for clinical and research use," a researcher said.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN